CLiC Poll #1: Excluding patients with del(17p)/TP53 mutation, which patients should be receiving chemo-immunotherapy firstline for CLL today?

If you haven’t yet participated in the poll, we invite you to share your views on Chemo-Immunotherapy for CLL:

Excluding patients with del(17p)/TP53 mutation, which patients should be receiving chemo-immunotherapy firstline for CLL today?

  • None – every patient should be receiving novel agents firstline today
  • Only young, fit with mutated IgVH who are eligible for curative-intent FCR
  • All patients except young and fit with unmutated IgHV
  • All patients firstline

Click here to answer

CLiC Webinar Thurs, Nov 22, 2018 at 8:00 pm EST: Join CLiC leaders to review key questions in CLL

Please join CLiC scientific committee leaders Dr. Carolyn Owen, Dr. Versha Banerji and Dr. Laurie Sehn for a webinar Thursday, Nov 22, 8:00 pm EST to review the recent online discussion in the CLiC community around the following questions:

 

CLiC Question #4: How do you transition patients from a BCRi agent to venetoclax? (2 replies to date)

CLiC Question #5: How often should you dose reduce ibrutinib for toxicity? Do you think that lower doses are better tolerated or that dose reductions are unwise? (1 reply to date)

CLiC Question #6: Which patients are appropriate for first-line ibrutinib? (no replies to date)

Webinar connection details are included in the calendar invite emailed to you on Oct 31. If you have any questions about the webinar or how to connect, please contact paul.abbass@legitimed.com.
Prior to the webinar, you are invited to visit the CLiC community on Sosido to review the questions & responses and to reply with your personal clinical perspectives.

 

View the CLiC MicroModule Video “A Summary of Discussions Surrounding CLL Treatment”: Now Available Online

We invite you to review the CLiC micromodule video titled “A Summary of Discussions Surrounding CLL Treatment”, reviewing the key points of the in-depth discussions held by the CLiC community in the first half of 2018. The video is approximately 10 minutes in length.

Watch the micromodules here:

English: http://bit.ly/2Ii4Xl0

French: http://bit.ly/2MRaeo3

CLiC Webinar Wed, May 9, 2018 at 7:00 pm EST: Join CLiC leaders to review key questions in CLL

Please join CLiC scientific committee leaders Dr. Carolyn Owen, Dr. Graeme Fraser, and Dr. April Shamy for a webinar Wednesday, May 9, 7:00 pm EST (access info was sent to you by email on April 30) to review the recent online discussion in the CLiC community around the following questions:

Webinar connection details were sent to you by email on April 30 – please check your inbox. If you have any questions about the webinar or how to connect, please contact paul.abbass@legitimed.com.

Prior to the webinar, you are invited to visit the CLiC community on Sosido to review the questions & responses and to reply with your personal clinical perspectives

Introducing MedViewTV ASH 2017 CLL Report & Video Interviews. Click to view late-breaker session with Dr. John Seymour and the MURANO Study

On behalf of Dr. Carolyn Owen (CLiC Chair) we wish to share MedViewTV and its inaugural Report from the Annual Meeting of the American Society of Hematology (ASH) Atlanta, Georgia / December 9-12, 2017, A New Era of Chemotherapy-free Treatments Emerges for Chronic Lymphocytic Leukemia (CLL) with permission from the Medical Education  Network (MedNet).

Atlanta – The recent approvals of many effective, well-tolerated novel agents for chronic lymphocytic leukemia (CLL) have changed the treatment landscape. Researchers are learning how best to sequence and potentially combine novel agents, including ibrutinib, idelalisib, and venetoclax, both with respect to chemo-immunotherapy and other novel agents. A handful of combination and single-agent CLL therapies show promising results, according to reports at ASH 2017. A major aim of CLL treatment is to eradicate detectable minimal residual disease (MRD), which is associated with improved outcomes regardless of the therapy used to achieve it. Deep remissions, including MRD negativity may be achieved with the added benefit of fixed duration of therapy. A consistent safety profile is also important to expand therapy to as many patients as possible … (more)

This week we feature coverage of the ASH 2017 Late-breaker session with Dr. John Seymour and the MURANO Study. To view, click here: http://bit.ly/2pqSLog